ABCL

AbCellera Biologics (ABCL)

About AbCellera Biologics (ABCL)

AbCellera Biologics, Inc. engages in the development of therapeutic antibodies. It offers antibody discovery platform that searches, decodes and analyzes natural immune systems to find antibodies that can be developed to prevent and treat disease. The company was founded by Carl Lars G. Hensen, Kathleen Lisaingo, Kevin Heyries, Véronique Lecault and Daniel Da Costa on November 8, 2012 and is headquartered in Vancouver, Canada.

Details

Daily high

$2.59

Daily low

$2.43

Price at open

$2.58

52 Week High

$6.06

52 Week Low

$2.34

Market cap

763.2M

Dividend yield

0.00%

Volume

1.5M

Avg. volume

1.7M

P/E ratio

-4.93

AbCellera Biologics News